Resilience to Antibiotic-induced Obesogenic Microbiota Vertically Transferred to the Neonatal Gut: Discovering Mechanism of Microbiota Modulation

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: Newborn
Healthy Volunteers: f
View:

• Pregnant women (n=125) and their newborn children who receive antibiotic treatment at delivery.

Locations
Other Locations
Finland
Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku
RECRUITING
Turku
Contact Information
Primary
Paula Tähtinen, MD, PhD
paula.tahtinen@utu.fi
+358-2-3130746
Time Frame
Start Date: 2024-05-08
Estimated Completion Date: 2029-12
Participants
Target number of participants: 125
Treatments
Active_comparator: Synbiotic
Bifidobacterium bifidum and human milk oligosaccharides (HMOs)
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Collaborators: Lallemand Health Solutions
Leads: Turku University Hospital

This content was sourced from clinicaltrials.gov